No price history available for this symbol yet.
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Sector
Drug Manufacturers - Specialty & Generic
Eris Lifesciences Limited is an Indian pharmaceutical company engaged in the manufacturing, marketing, and distribution of medicinal products throughout the country. The company provides a comprehensive range of branded formulations, catering to a wide spectrum of therapeutic areas. These encompass cardiovascular health, anti-diabetic treatments, anti-infectives, antipyretics, vitamin/nutrient supplements, gastroenterology, respiratory care, gynecology, pediatrics, neurology, psychiatry, and pain/analgesics, alongside services in in-vitro fertilization, cosmetology, and dermatology. Founded in 2007, Eris Lifesciences Limited is headquartered in Ahmedabad, India.
www.eris.co.inNo one on the platform currently holds ERIS.NS.
No tracked institution reports a position in ERIS.NS as of their last filing.
No one on the platform has traded ERIS.NS yet.
Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.
Consensus does not cover every selected forecast year. Later assumptions are extrapolated from available analyst estimates.
| Metric | Historical average | My assumptions | ||||
|---|---|---|---|---|---|---|
| 1 year | 5 years | 10 years | Low | Mid | High | |
| ROIC % | 13.7% | 13.2% | 19.7% | — | — | — |
| Rev. Growth % | 8.7% | 21.3% | ||||
| Profit Margin % | 19.8% | 21.1% | 26.2% | |||
| Free Cash Flow Margin % | 1.6% | 7.5% | 14.3% | |||
| Exit P/E | — | — | — | |||
| Exit P/FCF | — | — | — | |||
| Desired Annual Return % | — | — | — | |||
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2027 | $35.4B | +9.8% | $46.43 | $42.29–$51.56 | — | 8 |
| 2028 | $40.1B | +13.3% | $59.50 | $51.52–$65.92 | — | 9 |
| 2029 | $44.9B | +12.0% | $70.01 | $58.54–$79.79 | — | 6 |
| 2030 | $52.0B | +15.8% | $77.00 | $74.72–$79.53 | — | 2 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
Beat consensus in 2 of the last 8 reported quarters
| Reported | Est. EPS | Actual | Surprise |
|---|---|---|---|
| 2026-07-29 | $10.77 | $10.30 | -4.4% |
| 2026-05-20 | $9.43 | $9.50 | +0.7% |
| 2026-02-13 | $9.63 | $8.30 | -13.8% |
| 2025-10-23 | $9.00 | $8.80 | -2.2% |
| 2025-08-05 | $8.52 | $8.70 | +2.1% |
| 2025-05-19 | $7.00 | $6.88 | -1.7% |
| 2025-02-04 | $6.57 | $6.10 | -7.2% |
| 2024-10-25 | $7.00 |
| Symbol | Price | Today | Mkt cap | P/E |
|---|---|---|---|---|
| ERIS.NSEris Lifesciences Limited | $1310.10 | -3.35% | $181.6B | — |
| APLLTD.BOAlembic Pharmaceuticals Limited | $822.40 | +1.47% | $161.6B | — |
| APLLTD.NSAlembic Pharmaceuticals Limited | $824.75 | +1.70% | $162.1B | — |
| ASTRAZEN.NSAstraZeneca Pharma India Limited | $6695.50 | -1.02% | $167.4B | — |
| JUBLPHARMA.BOJubilant Pharmova Limited |
| $6.72 |
| -4.0% |
| $1009.60 |
| -1.51% |
| $160.1B |
| — |
| JUBLPHARMA.NSJubilant Pharmova Limited | $1011.95 | -1.29% | $160.3B | — |
| NEULANDLAB.BONeuland Laboratories Limited | $22522.85 | -3.87% | $289.5B | — |
Source: Financial Modeling Prep · peers by sector/industry